Noninvasive biomarkers for the diagnosis and management of autoimmune hepatitis

Claire Harrington, Swathi Krishnan, Cara L. Mack, Paolo Cravedi, David N. Assis, Josh Levitsky*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

1 Scopus citations

Abstract

Autoimmune hepatitis (AIH) is a rare disease of unclear etiology characterized by loss of self-tolerance that can lead to liver injury, cirrhosis, and acute liver failure. First-line treatment consists of systemic corticosteroids, or budesonide, and azathioprine, to which most patients are initially responsive, although predictors of response are lacking. Relapses are very common, correlate with histological activity despite normal serum transaminases, and increase hepatic fibrosis. Furthermore, current regimens lead to adverse effects and reduced quality of life, whereas medication titration is imprecise. Biomarkers that can predict the clinical course of disease, identify patients at elevated risk for relapse, and improve monitoring and medication dosing beyond current practice would have high clinical value. Herein, we review novel candidate biomarkers in adult and pediatric AIH based on prespecified criteria, including gene expression profiles, proteins, metabolites, and immune cell phenotypes in different stages of AIH. We also discuss biomarkers relevant to AIH from other immune diseases. We conclude with proposed future directions in which biomarker implementation into clinical practice could lead to advances in personalized therapeutic management of AIH.

Original languageEnglish (US)
Pages (from-to)1862-1879
Number of pages18
JournalHepatology
Volume76
Issue number6
DOIs
StatePublished - Dec 2022

ASJC Scopus subject areas

  • Hepatology

Fingerprint

Dive into the research topics of 'Noninvasive biomarkers for the diagnosis and management of autoimmune hepatitis'. Together they form a unique fingerprint.

Cite this